Bristol-Myers Squibb vs NVIDIA: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. NVIDIA was founded in 1993 by Jensen Huang, Chris Malachowsky, Curtis Priem and is led by Jensen Huang.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
NVIDIA
- Founded
- 1993
- Headquarters
- Santa Clara, California, United States
- Current CEO
- Jensen Huang
- Employees
- 42,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
NVIDIA
Jensen Huang
Nvidia possesses a gritty, prescient founding story, rooted entirely in a specific, technical conversation at a well-known American diner, and driven by a CEO who possessed an unshakable conviction in an unproven computational theory.
Chris Malachowsky
Chris Malachowsky co-founded NVIDIA in 1993 and became a central figure in the company's technical foundation.
Curtis Priem
Curtis Priem co-founded NVIDIA in 1993 and served as one of the company's original architects.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
NVIDIA
- Jensen Huang1993–present
CEO
Huang has been CEO for more than 33 years, which makes him one of the longest-serving founder-CEOs in the industry. Under him NVIDIA bet early on CUDA and deep learning, bought Mellanox for networking, and moved to a yearly architecture cadence.
Source - Chris Malachowsky1993–2024
Co-Founder
Chris Malachowsky co-founded Nvidia in 1993. As Senior Vice President of Engineering and Operations, he played a critical role in developing the early graphics processing architecture and establishing Nvidia's robust engineering supply chain.
Source - Colette Kress2013–present
Executive Vice President and Chief Financial Officer
She has been CFO through NVIDIA's growth from about $4B of annual revenue to $215.9B in FY2026, and she leads its quarterly earnings communication with investors.
Source
Timeline: Bristol-Myers Squibb and NVIDIA side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1993NVIDIA
Founding in Santa Clara
Jensen Huang, Chris Malachowsky, and Curtis Priem founded NVIDIA on April 5, 1993, with a focus on 3D graphics for gaming and multimedia. The founding set the company on a parallel-processing path long before AI infrastructure became the main market.
1999NVIDIA
GPU Category Defined
NVIDIA introduced the graphics processing unit concept in 1999. The milestone mattered because it framed graphics hardware as a specialized processor, a technical idea that later carried into accelerated computing and AI workloads.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2006NVIDIA
CUDA Opens GPUs to General Computing
CUDA opened GPU parallel processing to scientists, researchers, and developers outside graphics. It became the software foundation that made NVIDIA hardware useful for machine learning, simulation, and other compute-heavy workloads.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2012NVIDIA
AlexNet Shows GPU Value for Deep Learning
The AlexNet breakthrough used NVIDIA GPUs to win the ImageNet competition. The event helped convince researchers and engineers that GPUs could accelerate neural-network training at a scale CPUs could not match.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2016NVIDIA
DGX-1 AI Supercomputer
Nvidia introduced the DGX-1 deep-learning supercomputer in 2016, its first system built specifically for artificial intelligence.
2018NVIDIA
RTX Brings Real-Time Ray Tracing to Graphics
NVIDIA RTX brought real-time ray tracing into the company's graphics roadmap. The product line kept gaming and professional visualization tied to AI-enhanced rendering while Data Center was becoming more important.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020NVIDIA
Mellanox Acquisition Adds Networking
NVIDIA completed the Mellanox acquisition for about $7 billion. The deal mattered because large AI and high-performance-computing clusters depend on fast networking between accelerators, not only on individual GPU speed.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022NVIDIA
Arm Acquisition Terminated
NVIDIA and SoftBank terminated the proposed Arm acquisition because of significant regulatory challenges. The failed deal showed how closely governments watch control points in semiconductor architecture.
2022NVIDIA
Hopper H100 Announced
Nvidia announced the Hopper-architecture H100 data-center GPU in March 2022.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023NVIDIA
Grace CPU Enters Data Center Roadmap
NVIDIA introduced its first data-center CPU, Grace, for large-scale AI and high-performance computing. The milestone expanded the platform from GPUs and networking into CPU-GPU system design.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2024NVIDIA
Blackwell Architecture Launched
NVIDIA launched Blackwell as a data-center-scale architecture combining GPUs, CPUs, DPUs, interconnects, switch chips, systems, and networking adapters. The architecture became central to FY2026 Data Center demand.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026NVIDIA
$215.9B FY2026 Revenue
NVIDIA reported $215.9 billion of FY2026 revenue, $193.7 billion of Data Center revenue, and $120.1 billion of net income. The result showed how far AI infrastructure had moved the company beyond its original PC graphics market.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
NVIDIA
- Groq (technology license and team)2025Undisclosed
- Run:ai2024$700M
- Excelero2022Undisclosed
- Mellanox Technologies2020$6.9B
- Cumulus Networks2020Undisclosed
- Icera2011$367M
Questions about Bristol-Myers Squibb vs NVIDIA
Who is the CEO of Bristol-Myers Squibb Company and NVIDIA Corporation?
Bristol-Myers Squibb Company is led by Christopher Boerner and NVIDIA Corporation is led by Jensen Huang. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs NVIDIA Corporation?
Bristol-Myers Squibb Company was founded in 1887 — 106 years before NVIDIA Corporation, which was founded in 1993. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger NVIDIA Corporation.
How many employees does Bristol-Myers Squibb Company have compared to NVIDIA Corporation?
Bristol-Myers Squibb Company employs approximately 32,500 people, while NVIDIA Corporation employs approximately 42,000. NVIDIA Corporation has the larger workforce at 42,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and NVIDIA Corporation headquartered?
Both Bristol-Myers Squibb Company and NVIDIA Corporation are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and NVIDIA Corporation?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. NVIDIA Corporation was founded by Jensen Huang, Chris Malachowsky, Curtis Priem.
Which company has a longer operating history — Bristol-Myers Squibb Company or NVIDIA Corporation?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. NVIDIA Corporation has been in operation for around 33 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs NVIDIA overview